Bulkamid typically provides meaningful improvement in stress urinary incontinence for at least three to seven years, though its effectiveness gradually declines over time. In the longest published study, about 67% of women who received Bulkamid as their first treatment still reported feeling cured or improved at seven years. That’s a solid result for a minimally invasive injection, but it also means roughly a third of patients will need additional treatment within that window.
What the Long-Term Data Shows
The best way to understand how long Bulkamid lasts is to follow the numbers over time. In the first year after treatment, about 66% of patients report being cured or significantly improved. A larger study of 256 women found an initial success rate of 82%, which held at a median follow-up of just over three years. At seven years, the longest follow-up available, 67% of women who had Bulkamid as a primary procedure still felt their symptoms were cured or improved.
These numbers tell an encouraging story, but they also reveal a pattern: the strongest results come in the first few years, and some patients experience a gradual return of leakage. The gel itself doesn’t dissolve. Bulkamid is a nondegradable hydrogel that integrates into the surrounding tissue with minimal reaction from the body. But the tissue around it can change with aging, hormonal shifts, or other factors, which may reduce the bulking effect over time.
How Often Repeat Injections Are Needed
Most women need more than one injection session to get the best result. In the FDA clinical study, only about 23% of patients achieved their desired outcome with a single session. Around 42% needed two sessions, and 36% needed three. These aren’t signs of failure. They’re part of the standard treatment plan, with each session fine-tuning the placement and volume of gel.
Beyond those initial sessions, retreatment for returning symptoms is common over the longer term. In a large retrospective study, about 20% of women who received urethral bulking agents needed a repeat injection within the first year, and roughly 25% were retreated within five years. Another analysis found that 32% required repeat bulking and 19% went on to have a different surgical procedure within seven years. If a top-up injection is needed, it can be done as early as four weeks after the previous session.
How Bulkamid Compares to Sling Surgery
The mid-urethral sling is the most established surgical option for stress incontinence, and it lasts significantly longer than Bulkamid on average. The five-year retreatment rate for slings is around 3.8%, compared to about 25% for urethral bulking. In a study of Medicare patients followed for a median of about five years, 10% of sling patients needed a repeat procedure of any kind, compared to 36% of bulking patients. The median time to a repeat procedure was five years for sling patients and 3.3 years for those who chose bulking.
That gap is real, but it doesn’t make Bulkamid the wrong choice for everyone. Slings carry a higher risk of surgical complications. In the same study, 3.4% of sling patients needed reoperation for complications within five years, compared to 1.5% of bulking patients. Bulkamid is an office procedure done under local anesthesia with minimal downtime, while sling placement is a more involved surgery. For women who want to avoid the operating room, who have other health conditions that increase surgical risk, or who prefer a less invasive first step, the trade-off between durability and simplicity can be worthwhile.
What Affects How Long It Works
Several factors influence how much benefit you get and how long it holds. Women who receive Bulkamid as their first incontinence treatment tend to have better long-term outcomes than those who’ve already had other procedures. The severity of leakage matters too. Bulkamid works best for mild to moderate stress incontinence, the kind triggered by coughing, sneezing, or exercise. Women with more severe leakage are more likely to need retreatment or eventually move to a surgical option.
The number and precision of injection sessions also play a role. Because most patients need two or three sessions to optimize the result, committing to the follow-up appointments is important. Skipping a recommended top-up session may leave the initial result less durable than it could be.
What to Realistically Expect
Bulkamid offers a meaningful window of improvement with very low procedural risk. Most women notice improvement quickly after treatment, and the majority maintain that benefit for several years. The realistic expectation is that you’ll likely need at least two injection sessions upfront, and there’s roughly a one-in-four chance you’ll need retreatment within five years. If the effect does fade, the procedure is easily repeatable, and having Bulkamid doesn’t prevent you from pursuing sling surgery later if you decide you want a more durable fix.
The gel stays in place permanently once injected, integrating into the tissue without migrating or being absorbed. What changes is the surrounding anatomy, which is why the functional benefit can diminish even though the material itself remains stable.